Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

Regional Metabolic Center, Los Angeles, California, United States
Children's Hospital Oakland, Oakland, California, United States
Emory University, Decatur, Georgia, United States
Feinberg School of Medicine, Chicago, Illinois, United States
Children's of Minnesota, Minneapolis, Minnesota, United States
Children's Mercy Hospital and Clinic, Kansas City, Missouri, United States
NYU School of Medicine, New York, New York, United States
Cincinatti Children's Hospital, Cincinnati, Ohio, United States
Texas Children's Hospital, Houston, Texas, United States
Medical Genetics/Pediatrics, Salt Lake City, Utah, United States
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Shaare Zedek Medical Center, Jerusalem, , Israel
Children's Memorial Health Institute, Warszawa, , Poland
Hospital Universitario Miguel Servet, Zaragoza, , Spain
The Royal Free Hospital, London, , United Kingdom

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the safety and efficacy of every other week dosing of GA-GCB (velaglucerase alfa) in participants with type 1 Gaucher disease who were previously treated with imiglucerase.